These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17173664)

  • 41. Homer expression in the hippocampus of an animal model of attention-deficit/hyperactivity disorder.
    Hong Q; Wang YP; Zhang M; Pan XQ; Guo M; Li F; Tong ML; Chen RH; Guo XR; Chi X
    Mol Med Rep; 2011; 4(4):705-12. PubMed ID: 21523321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder.
    Kantak KM; Singh T; Kerstetter KA; Dembro KA; Mutebi MM; Harvey RC; Deschepper CF; Dwoskin LP
    Behav Neurosci; 2008 Apr; 122(2):340-57. PubMed ID: 18410173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder.
    Hunt RD; Arnsten AF; Asbell MD
    J Am Acad Child Adolesc Psychiatry; 1995 Jan; 34(1):50-4. PubMed ID: 7860456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Noradrenergic Modulation of Learned and Innate Behaviors in Dopamine Transporter Knockout Rats by Guanfacine.
    Volnova A; Kurzina N; Belskaya A; Gromova A; Pelevin A; Ptukha M; Fesenko Z; Ignashchenkova A; Gainetdinov RR
    Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic caffeine treatment during prepubertal period confers long-term cognitive benefits in adult spontaneously hypertensive rats (SHR), an animal model of attention deficit hyperactivity disorder (ADHD).
    Pires VA; Pamplona FA; Pandolfo P; Prediger RD; Takahashi RN
    Behav Brain Res; 2010 Dec; 215(1):39-44. PubMed ID: 20600342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stimulus control in two rodent models of attention-deficit/hyperactivity disorder.
    Fox AE; Caramia SR; Haskell MM; Ramey AL; Singha D
    Behav Processes; 2017 Feb; 135():16-24. PubMed ID: 27864066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 5,7-Dihydroxy-6-methoxy-4'-phenoxyflavone, a derivative of oroxylin A improves attention-deficit/hyperactivity disorder (ADHD)-like behaviors in spontaneously hypertensive rats.
    dela Peña IC; Young Yoon S; Kim Y; Park H; Man Kim K; Hoon Ryu J; Young Shin C; Hoon Cheong J
    Eur J Pharmacol; 2013 Sep; 715(1-3):337-44. PubMed ID: 23707903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Animal models of attention-deficit hyperactivity disorder.
    Russell VA; Sagvolden T; Johansen EB
    Behav Brain Funct; 2005 Jul; 1():9. PubMed ID: 16022733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) -- the spontaneously hypertensive rat (SHR).
    Prediger RD; Pamplona FA; Fernandes D; Takahashi RN
    Int J Neuropsychopharmacol; 2005 Dec; 8(4):583-94. PubMed ID: 15877934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reprint of "Problems with spontaneously hypertensive rats (SHR) as a model of attention-deficit/hyperactivity disorder (AD/HD)".
    Alsop B
    J Neurosci Methods; 2007 Nov; 166(2):XV-XXI. PubMed ID: 17980764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A simple behavioral paradigm to measure impulsive behavior in an animal model of attention deficit hyperactivity disorder (ADHD) of the spontaneously hypertensive rats.
    Kim P; Choi I; Pena IC; Kim HJ; Kwon KJ; Park JH; Han SH; Ryu JH; Cheong JH; Shin CY
    Biomol Ther (Seoul); 2012 Jan; 20(1):125-31. PubMed ID: 24116285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alpha 2A adrenergic receptor agonist, guanfacine, attenuates cocaine-related impairments of inhibitory response control and working memory in animal models.
    Terry AV; Callahan PM; Schade R; Kille NJ; Plagenhoef M
    Pharmacol Biochem Behav; 2014 Nov; 126():63-72. PubMed ID: 25242808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of α-2A adrenergic receptor agonist on time and risk preference in primates.
    Kim S; Bobeica I; Gamo NJ; Arnsten AF; Lee D
    Psychopharmacology (Berl); 2012 Jan; 219(2):363-75. PubMed ID: 21979441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys.
    Steere JC; Arnsten AF
    Behav Neurosci; 1997 Oct; 111(5):883-91. PubMed ID: 9383511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Memory deficits and hippocampal cytokine expression in a rat model of ADHD.
    Anderson LG; Vogiatzoglou E; Tang S; Luiz S; Duque T; Ghaly JP; Schwartzer JJ; Hales JB; Sabariego M
    Brain Behav Immun Health; 2024 Feb; 35():100700. PubMed ID: 38107021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.
    Arnsten AF; Jin LE
    Yale J Biol Med; 2012 Mar; 85(1):45-58. PubMed ID: 22461743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast.
    Easton N; Shah YB; Marshall FH; Fone KC; Marsden CA
    Psychopharmacology (Berl); 2006 Dec; 189(3):369-85. PubMed ID: 17016709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disturbed relationship between glucocorticoid receptor and 5-HT1AR/5-HT2AR in ADHD rats: A correlation study.
    Lin X; Huang L; Huang H; Ke Z; Chen Y
    Front Neurosci; 2022; 16():1064369. PubMed ID: 36699537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Calcyon mRNA expression in the frontal-striatal circuitry and its relationship to vesicular processes and ADHD.
    Heijtz RD; Alexeyenko A; Castellanos FX
    Behav Brain Funct; 2007 Jul; 3():33. PubMed ID: 17623072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methylphenidate and Guanfacine Ameliorate ADHD-Like Phenotypes in
    Sumitomo A; Saka A; Ueta K; Horike K; Hirai K; Gamo NJ; Hikida T; Nakayama KI; Sawa A; Sakurai T; Tomoda T
    Mol Neuropsychiatry; 2018 May; 3(4):223-233. PubMed ID: 29888233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.